FDA grants Roche’s pertuzumab Priority Review for previously untreated HER2-positive metastatic breast cancer
8 February 2012 | By Roche
The U.S. FDA has accepted the company’s Biologics License Application for pertuzumab...
List view / Grid view
8 February 2012 | By Roche
The U.S. FDA has accepted the company’s Biologics License Application for pertuzumab...
8 February 2012 | By Amgen
Amgen to discuss the data from the sBLA for XGEVA® (denosumab)...
8 February 2012 | By Abbott
Abbott introduces Similac SimplySmart, an innovative BPA-free baby bottle designed to improve the bottle feeding experience...
7 February 2012 | By Merck
Company will review data from TRA-2P and TRACER with external experts to inform next steps...
6 February 2012 | By F T I Consulting
GSK announced that it will invest $60 million to expand its manufacturing and new drug development activities in Victoria...
6 February 2012 | By Merck
Company Confirms Plans to File NDA for Suvorexant in 2012...
6 February 2012 | By Chamberlain Healthcare PR
The European Commission has approved the use of Galvus® (vildagliptin)...
6 February 2012 | By kdm communications limited
Tecan has partnered with Artel...
3 February 2012 | By Bristol-Myers Squibb Company
Expiration of the HSR waiting period for acquisition of Inhibitex, Inc...
3 February 2012 | By Boehringer Ingelheim
Research collaboration agreement to develop new insights into the causes of diabetes...
2 February 2012 | By Merck
JANUMET XR can help many patients reach blood sugar goals...
2 February 2012 | By AstraZeneca
AstraZeneca has announced new restructuring initiatives designed to improve productivity and strengthen the company’s capabilities...
1 February 2012 | By Novartis
The US Food and Drug Administration has approved an update to the Glivec® (imatinib)* label...
30 January 2012 | By
Partners pledge innovative, coordinated action aimed at new WHO goals...
30 January 2012 | By Novartis
Novartis is a part of an international effort to eliminate or control 10 NTDs by the end of the decade...